Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 22;5(1):vdad123. doi: 10.1093/noajnl/vdad123

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 4. — Patient average PTA and WRS over the course of bevacizumab therapy. Timepoints of audiological data collection correspond to the closest evaluation prior to bevacizumab therapy, the closest evaluation following bevacizumab termination, and the closest evaluation at approximately 1 year following bevacizumab termination. (A) Average PTA at onset of therapy (“pretreatment”) was 38.7 ± 29.3 dB, 44.9 ± 30.1 dB at end-of-treatment/most recent for those still on therapy (“immediate postreatment”), and 62.6 ± 39.3 dB one year after therapy (“1 year posttreatment”). No significant difference between groups, P = .330. (B) Average WRS at onset of therapy (“pretreatment”) was 65.7 ± 38.4%, 74.2 ± 34.5% at end-of-treatment/most recent for those still on therapy (“immediate postreatment”), and 54.4 ± 38.1% 1 year after therapy (“1 year posttreatment”). No significant difference between groups, P = .371.